Monopar Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Developments
Monopar Therapeutics Inc. (MNPR)
Company Research
Source: GlobeNewswire
WILMETTE, Ill., March 28, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, today announced fourth quarter and full-year 2023 financial results and summarized recent developments. Recent Developments Novel MNPR-101 Radiopharmaceutical Program targeting uPAR – Phase 1 dosimetry clinical trial to commence in the coming weeks MNPR-101-Zr Phase 1 dosimetry clinical trial has Human Research Ethics Committee (HREC) clearance in Australia and is on track to initiate at the Melbourne Theranostic Innovation Centre (MTIC) within the next few weeks. Will enroll patients with advanced cancers, aiming for those most likely to have uPAR expression, which include a majority of all triple-negative breast, colorectal, and pancreatic cancers. Will utilize state-of-the-art positron emission tomography (PET) imaging to assess tumor uptake, normal organ biodistribution, and sa
Show less
Read more
Impact Snapshot
Event Time:
MNPR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MNPR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MNPR alerts
High impacting Monopar Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
MNPR
News
- Monopar Announces Radiopharma Presentation Selected for Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting [Yahoo! Finance]Yahoo! Finance
- Monopar Announces Radiopharma Presentation Selected for Society of Nuclear Medicine and Molecular Imaging 2024 Annual MeetingGlobeNewswire
- Monopar Announces Filing of Patent Protecting MNPR-101 Radiopharma Optimization Findings [Yahoo! Finance]Yahoo! Finance
- Monopar Announces Filing of Patent Protecting MNPR-101 Radiopharma Optimization FindingsGlobeNewswire
- Monopar Therapeutics Inc. (NASDAQ: MNPR) was upgraded by analysts at Jonestrading from a "hold" rating to a "buy" rating. They now have a $2.00 price target on the stock.MarketBeat
MNPR
Sec Filings
- 4/16/24 - Form 8-K
- 4/10/24 - Form 8-K
- 4/2/24 - Form 4
- MNPR's page on the SEC website